2019 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):

  • Silent period                                                   10 January 2019
  • Annual report 2018                                         7 February 2019
  • Annual General Meeting to be held                  13 March 2019
    at ALK                                                                        4.00 p.m.
    Bøge Allé 1
    2970 Hørsholm, Denmark

    Written requests to have specific business
    transacted at the AGM will be included in the
    agenda if received by the company on
    29 January 2019 at the latest
    (may be e-mailed to investor@alk.net)

  • Silent period                                                         11 April 2019
  • Three-month interim report (Q1) 2019                   9 May 2019
  • Silent period                                                         16 July 2019
  • Six-month interim report (Q2) 2019                 13 August 2019
  • Silent period                                                   10 October 2019
  • Nine-month interim report (Q3) 2019           7 November 2019

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment